PAR 12.7% 31.0¢ paradigm biopharmaceuticals limited..

Ann: iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study, page-55

  1. 9,883 Posts.
    lightbulb Created with Sketch. 224
    I believe there may still be a question in the market about how long this will take to be commercial, and how much more money it will take to get there.

    This is a great step, very positive, but we are still a VERY long way from anything substantive in terms of major SP re-rate in my opinion.

    Actually hope I'm wrong, but either way, I am holding with confidence, but with the drawer closed for a while now.

    GLTA

    Cabe

 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.